Investor Presentation - First Six Months of 2021

46 Investor presentation First six months of 2021 Novo NordiskⓇ GLP-1 effect dependent on blood glucose level GLP-1 mechanism of action when blood sugar levels increase Creates sense of satiety in the brain Brain Diabetes CVD Reduces glucagon secretion in the liver GLP-1 Liver Slows gastric emptying in the gut Obesity Gut NASH CKD Semaglutide holds a plethora of therapeutic opportunities¹ FORTE - Semaglutide 2.0 mg Semaglutide s.c. ~961 patients, T2D FOCUS - Diabetic retinopathy outcomes trial Semaglutide s.c; ~1,500 patients, T2D ≥10 years SOUL - Cardiovascular outcomes trial Oral semaglutide; ~9,600 patients, T2D, established CVD or CKD SELECT - Cardiovascular outcomes trial Semaglutide 2.4 mg, ~17,500 patients with obesity and without diabetes, event driven Semaglutide in NASH Semaglutide s.c.; phase 2 trials FLOW - Chronic kidney disease outcomes trial Semaglutide 1.0 mg; ~3,200 patients, T2D, moderate to severe CKD Alzheimer's Disease Pancreas Increases insulin secretion in the pancreas Brain disorders Oral Semaglutide 14 mg; ~ 3,700 patients with early Alzheimer's disease 1 List is not exhaustive Sc: Subcutaneous; T2D: Type 2 diabetes; CVD: Cardiovascular disease; CKD: Chronic kidney disease

View entire presentation